FDA Begs OMB: Pretty Please Renew Our Defect Reporting Form?
Published Date: 9/16/2026
Notice
Summary
The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
45-Day Deviation Reporting Requirement
If you manufacture biological products, human blood and blood components, operate a registered blood establishment, or run a transfusion service, you must report biological product deviations using Form FDA 3486. The rule requires reports to be submitted to CBER or CDER “as soon as possible” but no later than 45 calendar days after you learn of a reportable event.
Estimated Annual Reporting Burden Increased
FDA estimates total annual responses of 17,818 and total annual burden of 34,191 hours for Form FDA 3486/3486A reporting. FDA states this reflects an overall increase of approximately 2,642 responses and 4,612 hours compared to prior estimates, largely from Sec. 606.171 reports (16,277 responses; 32,554 hours).
Electronic Filing and Addendum Details
CBER accepts electronic submissions of Form FDA 3486 and has a web-based addendum (Form FDA 3486A) to collect extra recall-related details; CDER does not currently accept electronic filings. CBER estimates 5 percent of BPD reports to CBER need the addendum, and the addendum takes about 15 minutes (0.25 hours) to complete.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18529, Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Tracking
The FDA wants your thoughts on how they collect info to track medical devices. This affects companies that make or handle these devices and aims to keep things safe and clear. You’ve got until November 10, 2026, to share your comments—no cost, just your voice!
2026-18612, Medical Devices; Cardiovascular Devices; Classification of the Cardiovascular Machine Learning-Based Notification Software
The Food and Drug Administration (FDA) is classifying the cardiovascular machine learning-based notification software into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the cardiovascular machine learning- based notification software. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18551, Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate
The Food and Drug Administration (FDA or Agency) is announcing the availability on its website of the final administrative order (final order) (OTC000008-1) titled "Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate." This final order amends "Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use" (Over- the-Counter (OTC) Monograph M020) to remove PABA and trolamine salicylate as sunscreen active ingredients. A sunscreen drug product containing PABA or trolamine salicylate is not generally recognized as safe and effective (GRASE).
Previous / Next Documents
Previous: 2026-18945, Crystalline Silicon Photovoltaic Cells, Whether or Not Assembled Into Modules From India: Final Affirmative Determination of Sales at Less Than Fair Value, and Final Affirmative Determination of Critical Circumstances, In Part
The U.S. Department of Commerce found that solar cells from India are being sold in the U.S. for less than their fair price. Starting September 16, 2026, this means importers might face extra duties to keep things fair for American businesses. This decision covers sales from July 2024 to June 2025 and aims to protect the U.S. solar market from unfair pricing.
Next: 2026-18947, Crystalline Silicon Photovoltaic Cells, Whether or Not Assembled Into Modules, From India: Final Affirmative Countervailing Duty Determination and the Final Affirmative Critical Circumstances Determination, in Part
The U.S. Department of Commerce (Commerce) determines that countervailable subsidies are being provided to producers and exporters of crystalline silicon photovoltaic cells, whether or not assembled into modules (solar cells) from India. The period of investigation is April 1, 2024, through March 31, 2025.